BR112015023783A2 - método para diagnóstico e tratamento de metastase no câncer - Google Patents

método para diagnóstico e tratamento de metastase no câncer

Info

Publication number
BR112015023783A2
BR112015023783A2 BR112015023783A BR112015023783A BR112015023783A2 BR 112015023783 A2 BR112015023783 A2 BR 112015023783A2 BR 112015023783 A BR112015023783 A BR 112015023783A BR 112015023783 A BR112015023783 A BR 112015023783A BR 112015023783 A2 BR112015023783 A2 BR 112015023783A2
Authority
BR
Brazil
Prior art keywords
relates
cancer
gene
interest
bone metastases
Prior art date
Application number
BR112015023783A
Other languages
English (en)
Inventor
Arnal Anna
Planet Evarist
Tarragona Maria
Pavlovic Milica
Gomis Roger
Original Assignee
Fundacio Inst De Recerca Biomedica Irb Barcelona
Inst Catalana Recerca Estudis Avancats
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Inst De Recerca Biomedica Irb Barcelona, Inst Catalana Recerca Estudis Avancats filed Critical Fundacio Inst De Recerca Biomedica Irb Barcelona
Publication of BR112015023783A2 publication Critical patent/BR112015023783A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Abstract

resumo “método para diagnóstico e tratamento de metastase no câncer” a presente invenção refere-se a um método para o diagnóstico de metásta-ses ósseas no câncer que compreende o uso de uma sonda para determinar se um gene de interesse é amplificado numa amostra do tumor primário. da mesma forma, a invenção também se refere a um método para a determinação da tendência para desenvolver metástase óssea em relação a metástases em outros órgãos, as quais compreendem, utilizar uma sonda para determinar o nível de expressão de um gene de interesse, ou a amplificação ou translocação de um gene de interesse. a inven-ção também se refere a um método para a previsão de metástases ósseas no início de um sujeito que sofre de câncer. a invenção também se relaciona com um inibidor de c-maf como agente terapêutico para uso no tratamento da metástase do câncer. a invenção refere-se a kits para a previsão de metástases ósseas e prever o resulta-do clínico de um sujeito que sofre de metástases ósseas. finalmente, a invenção refere-se a um método para a tipagem de um sujeito que sofre de câncer e para a classificação de um sujeito a partir de câncer em um coorte.
BR112015023783A 2013-03-15 2014-03-14 método para diagnóstico e tratamento de metastase no câncer BR112015023783A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361801718P 2013-03-15 2013-03-15
PCT/IB2014/001253 WO2014140933A2 (en) 2013-03-15 2014-03-14 Method for the prognosis and treatment of cancer metastasis

Publications (1)

Publication Number Publication Date
BR112015023783A2 true BR112015023783A2 (pt) 2017-10-24

Family

ID=51265712

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023783A BR112015023783A2 (pt) 2013-03-15 2014-03-14 método para diagnóstico e tratamento de metastase no câncer

Country Status (10)

Country Link
US (2) US20160032400A1 (pt)
EP (1) EP2971113B1 (pt)
JP (1) JP6577873B2 (pt)
KR (1) KR20150122731A (pt)
CN (1) CN105324491B (pt)
AU (1) AU2014229505B2 (pt)
BR (1) BR112015023783A2 (pt)
CA (1) CA2906394A1 (pt)
MX (2) MX2015011362A (pt)
WO (1) WO2014140933A2 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
EP2291553A4 (en) 2008-05-28 2011-12-14 Genomedx Biosciences Inc SYSTEMS AND METHODS FOR THE EXPRESSION-BASED DISTINCTION OF DIFFERENT CLINICAL ILLICIT STADIAS IN PROSTATE CANCER
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
US8669057B2 (en) 2009-05-07 2014-03-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
WO2012045905A2 (es) 2010-10-06 2012-04-12 Fundació Privada Institut De Recerca Biomèdica Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama
WO2013090620A1 (en) 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
EP2859120B1 (en) 2012-06-06 2018-11-14 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Method for the diagnosis and prognosis of lung cancer metastasis
EP2885640B1 (en) 2012-08-16 2018-07-18 Genomedx Biosciences, Inc. Prostate cancer prognostics using biomarkers
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
BR112015008255B1 (pt) 2012-10-12 2023-02-28 Inbiomotion S.L Métodos in vitro para diagnóstico ou prognóstico de metástase óssea em um indivíduo com câncer de próstata e método para classificar um indivíduo que sofre de câncer de próstata em uma coorte
EP2968988A4 (en) 2013-03-14 2016-11-16 Allegro Diagnostics Corp METHOD FOR EVALUATING A COPD STATUS
WO2014140896A2 (es) 2013-03-15 2014-09-18 Fundacio Privada Institut De Recerca Biomedica Metodo para el diagnostico, pronostico y tratamiento de la metastasis de un cancer
CN114606309A (zh) 2014-11-05 2022-06-10 威拉赛特公司 使用机器学习和高维转录数据的诊断系统和方法
CN107001480B (zh) 2014-12-11 2021-12-03 生物运动有限公司 用于人c-maf的结合成员
CA3015054A1 (en) * 2016-02-18 2017-08-24 Kyoto University Complex capable of inhibiting genetic function in exosome, and cancer proliferation and/or metastasis suppressor
US11013817B2 (en) * 2016-04-08 2021-05-25 The Cleveland Clinic Foundation Nanoparticles for drug delivery to treat bone disease
CA3023976A1 (en) * 2016-05-19 2017-11-23 Probiocon Gmbh Anti-cancer combination treatment
BR112018074076A2 (pt) * 2016-05-25 2019-03-06 Inbiomotion S.L. tratamento terapêutico de câncer de mama baseado em status c-maf
MX2019000353A (es) * 2016-07-12 2019-06-13 Univ North Carolina Chapel Hill Andamios de biomatriz para usarse en el diagnóstico y modelado del cáncer.
CN110506127B (zh) 2016-08-24 2024-01-12 维拉科特Sd公司 基因组标签预测前列腺癌患者对术后放射疗法应答性的用途
US11208697B2 (en) 2017-01-20 2021-12-28 Decipher Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
WO2018165600A1 (en) 2017-03-09 2018-09-13 Genomedx Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
CA3062716A1 (en) 2017-05-12 2018-11-15 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
KR20200104298A (ko) 2017-11-22 2020-09-03 인바이오모션 에스.엘. c-MAF 상태에 기반한 유방암의 요법 치료
CN108084254A (zh) * 2017-11-30 2018-05-29 天津市湖滨盘古基因科学发展有限公司 一种人的抗癌基因WWOXδ6-8突变蛋白及其应用
WO2021185959A1 (en) * 2020-03-19 2021-09-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Estrogen-related receptor alpha agonists for the treatment and the prognosis of bone metastases
CN115919464B (zh) * 2023-03-02 2023-06-23 四川爱麓智能科技有限公司 肿瘤定位方法、系统、装置及肿瘤发展预测方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3688418T2 (de) 1985-02-13 1993-08-26 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
CN1215432A (zh) 1996-04-05 1999-04-28 索尔克生物学研究所 调节外源性基因在哺乳动物系统中表达的激素介导的方法及其相关产物
JP4138013B2 (ja) 1996-12-23 2008-08-20 イミュネックス・コーポレーション Ｔｎｆスーパーファミリーのメンバーであるｎｆ−ｋａｐｐａ ｂの受容体アクティベーターに対するリガンド
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6274338B1 (en) 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
SK12882001A3 (sk) 1999-03-15 2002-04-04 Axys Pharmaceuticals, Inc. Zlúčeniny a prípravky ako proteinázové inhibítory
US6287813B1 (en) 1999-04-23 2001-09-11 Cistronics Cell Technology Gmbh Antibiotic-based gene regulation system
DE60132975T2 (de) 2000-01-06 2009-02-26 Merck Frosst Canada Inc., Kirkland Neue substanzen und verbindungen als protease-inhibitoren
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
CN103232539B (zh) 2001-06-26 2015-06-03 安姆根弗里蒙特公司 抗opgl抗体
AR036375A1 (es) 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
AU2003903540A0 (en) 2003-07-09 2003-07-24 Atdec Pty Ltd Flat panel display wall mounting system
WO2005026322A2 (en) 2003-09-11 2005-03-24 Clontech Laboratories, Inc. siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME
AU2003286499A1 (en) 2003-10-17 2004-06-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interference with c-maf function in multiple myeloma
US20090048117A1 (en) 2003-12-18 2009-02-19 President And Fellows Of Harvard College Modulation of immune system function by modulation of polypeptide arginine methyltransferases
TW200526224A (en) 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
WO2006012221A2 (en) 2004-06-25 2006-02-02 The Regents Of The University Of California Target cell-specific short interfering rna and methods of use thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
CA2632451C (en) 2005-12-06 2015-11-03 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
EP1984024A2 (en) * 2006-01-05 2008-10-29 Novartis AG Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
WO2008098351A1 (en) 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
NZ581097A (en) 2007-05-24 2012-03-30 Ablynx Nv Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
CA2729521A1 (en) * 2008-07-02 2010-01-07 Assistance Publique Hopitaux De Paris A method for predicting clinical outcome of patients with non-small cell lung carcinoma
WO2012045905A2 (es) * 2010-10-06 2012-04-12 Fundació Privada Institut De Recerca Biomèdica Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama
WO2012064967A2 (en) * 2010-11-10 2012-05-18 Cedars-Sinai Medical Center Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases
EP2650682A1 (en) * 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
EP2859120B1 (en) * 2012-06-06 2018-11-14 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Method for the diagnosis and prognosis of lung cancer metastasis

Also Published As

Publication number Publication date
EP2971113B1 (en) 2020-08-12
CA2906394A1 (en) 2014-09-18
AU2014229505B2 (en) 2020-02-27
CN105324491A (zh) 2016-02-10
WO2014140933A3 (en) 2014-12-31
US20160032400A1 (en) 2016-02-04
KR20150122731A (ko) 2015-11-02
MX2020001156A (es) 2020-03-12
JP6577873B2 (ja) 2019-09-18
MX2015011362A (es) 2015-12-16
EP2971113A2 (en) 2016-01-20
AU2014229505A1 (en) 2015-09-03
WO2014140933A8 (en) 2020-10-01
JP2016516403A (ja) 2016-06-09
US20210317534A1 (en) 2021-10-14
WO2014140933A2 (en) 2014-09-18
CN105324491B (zh) 2021-10-26

Similar Documents

Publication Publication Date Title
BR112015023783A2 (pt) método para diagnóstico e tratamento de metastase no câncer
BR112014025269A2 (pt) método para o prognóstico e tratamento de metástase de câncer
BR112016007864A2 (pt) método para a prognose e tratamento de metástase de câncer
BR112014030750A2 (pt) Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
BR112015008255A2 (pt) método para o diagnóstico, prognóstico e tratamento de metástase de câncer de próstata
Sackmann et al. Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group
BR112013008505A2 (pt) método para o diagnóstico, prognóstico e tratamento de metástase de câncer de mama
Adler et al. Metastatic pathways in patients with cutaneous melanoma
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
BR112012025593A2 (pt) biomarcadores em circulação para doença
BR112015004229A2 (pt) ensaios de diagnósticos e kits para a deteção de receptor 1 do folato
WO2014184679A3 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
BR112014002975A2 (pt) composições de biomarcador e métodos
BR112012026239A2 (pt) polinucleotídeo isolado, cassete de expressão, célula hospedeira, polipeptídeo isolado, animal transgênico não humano que foi alterado para expressar um polipeptídeo mutante com resistência a alk, anticorpo que se liga especificamente a um polipeptídeo mutante com resistência a alk, kit para detecção de uma mutação com resistência a inibidor de alk em uma amostra biológica, e, métodos para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pelo menos um inibidor de cinase de molécula pequena de alk, para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pf-02341066 em um paciente, de reduzir especificamente a expressão de um mutante com resistência a alk, de tratamento de um câncer associado com atividade de alç aberrante que é reistente a pelo mneos um inibidor de cinase de molécula pequena de alk, de traatamento de um câncer aberrante que é resistente a pf-02341066, de identificação de um agente capaz de inibir a atividade cinase de um mutante com resistência a alk ou proteína de fusão de alk
NZ609493A (en) Diagnosis and treatments relating to th2 inhibition
BRPI1007321A2 (pt) métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo.
BR112014031414A2 (pt) métodos de detectar doenças ou condições utilizando células doentes circulantes
BR112017025254A2 (pt) ?métodos para detecção de pelo menos uma mutação em uma pluralidade de genes relacionados ao câncer, selecionar um indivíduo para tratamento e prever a probabilidade de capacidade de resposta ao tratamento?
AR099856A1 (es) Métodos para diagnosticar y tratar la enfermedad de intestino inflamado
WO2009015050A3 (en) Gene expression profile for predicting ovarian cancer patient survival
BR112016024143A2 (pt) tratamento de câncer
BR112017022320A2 (pt) métodos para tratamento de câncer de pulmão
Motegi et al. Impact of expression of CD44, a cancer stem cell marker, on the treatment outcomes of intensity modulated radiation therapy in patients with oropharyngeal squamous cell carcinoma
MX352680B (es) Metodos y productos para el diagnostico in vitro, pronosticos in vitro y desarrollo de farmacos contra carcinomas invasivos.
Peltola et al. Correlation of c-Met expression and outcome in patients with renal cell carcinoma treated with sunitinib

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements